AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (MSOS)
3.4000
-0.1000 (-2.86%)
Tilray Brands Has Diversified Its Business Through Alcohol, but Is the Stock a Better Buy Than It Was 5 Years Ago?fool.com
Via The Motley Fool · January 22, 2025
Cannabis Legalization Headed For The Ballot Again In Florida: Advocates Launch New Amendment Initiativebenzinga.com
Group behind failed attempt to legalize recreational cannabis in FL has launched new initiative for 2026 ballot. Allows adult use with limits and restrictions.
Via Benzinga · January 15, 2025
Amplify To Liquidate Cannabis-Focused MJUS ETF As Regulatory Uncertainty Weighs On Sectorbenzinga.com
Amplify ETFs plans to liquidate MJUS, a cannabis-related ETF, due to regulatory issues. Other cannabis ETFs also struggling with DEA's indecisiveness.
Via Benzinga · January 8, 2025
DEA Accused Of Bias In Cannabis Rescheduling Hearings: Weed Stocks Plummeted In 2024 As Process Drags Onbenzinga.com
DEA judge orders agency to respond to allegations of opposing marijuana rescheduling and improper communication with opponents. Cannabis stocks declined in 2024 due to concerns about DEA review.
Via Benzinga · January 8, 2025
Turnaroud Tuesday: Did Canna Finally Bottom?talkmarkets.com
MSOS rose over 14% in today’s session. Interestingly, the price action was inside the trading range of Monday.
Via Talk Markets · November 12, 2024
EXCLUSIVE: Cannabis Physician Says Surgeon General's Alcohol Cancer Risk Warning Is 'Wake-Up Call'benzinga.com
Surgeon general warns about alcohol's cancer risk, suggests updates to health labels. Cannabis stocks largely rise while alcohol stocks drop.
Via Benzinga · January 3, 2025
Here's Why Tilray Brands' CEO Is Optimistic Marijuana Legalization Will Happen Under the Trump Administrationfool.com
Via The Motley Fool · December 31, 2024
Cannabis Reform 2024: The Year Of All Talk And No Actionbenzinga.com
In 2024, the cannabis landscape in the U.S. experienced some developments, though federal legalization or removal from the CSA.
Via Benzinga · December 27, 2024
Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?benzinga.com
For investors, MariMed represents a fundamentally strong outlier, but industry-wide challenges remain a drag on stock performance.
Via Benzinga · December 4, 2024
Cannabis Stocks Feel The Burn: Matt Gaetz Bows Out As Trump's Attorney General Nomineebenzinga.com
The AdvisorShares Pure US Cannabis ETF (NYSEMSOS), often viewed as a benchmark for MSOs, dropped by -4.31%, closing at $4.56.
Via Benzinga · November 21, 2024
Stocks Of The Day: 4-Pillar Power Plays You Can’t Miss - Today’s Biggest Moverstalkmarkets.com
Markets opened with a strong tailwind, driven by the latest CPI data showing inflation in line with expectations, bolstering investor confidence.
Via Talk Markets · November 13, 2024
Trump Nominates Another Cannabis Supporter To Cabinet: Rep. Matt Gaetz For Attorney Generalbenzinga.com
Donald Trump nominated Rep. Matt Gaetz as attorney general, who has supported cannabis legalization and proposed ending cannabis testing for military recruitment.
Via Benzinga · November 13, 2024
Matt Gaetz Is Trump's Attorney General Pick: Would-Be Top Cop Is Under House Ethics Investigationbenzinga.com
Matt Gaetz has been named the attorney general nominee by Donald Trump. The selection comes while Gaetz is being investigated by Congress.
Via Benzinga · November 13, 2024
Cannabis Stocks Pop Following Chris Christie's Prediction That Trump Will Deschedule Cannabisbenzinga.com
Cannabis stocks rally on prediction of Trump descheduling marijuana; MSOS leads gains with a 15% surge, followed by Cronos at nearly 13%.
Via Benzinga · November 12, 2024
The Good, The Bad, And The Ugly: A Recap Of Post-Vote Winners & Loserstalkmarkets.com
What’s promised on the campaign trail and what comes to reality are often different. But that didn’t stop investors and traders from speculating on the most prevalent themes under a new administration. Here's a look at what moved and why.
Via Talk Markets · November 10, 2024
Cannabis Stocks: Is It Time To Buy The Dip After Elections And Legalization Setbacks?benzinga.com
After a post-election plunge, cannabis stocks are showing signs of recovery. We analyze Tilray, SNDL, Trulieve, MSOS – time to buy the dip?
Via Benzinga · November 7, 2024
Cannabis Stocks Collapse After Trump Win: Major Players See Double-Digit Declines At Wednesday's Closebenzinga.com
Following Trump's presidential election victory, the cannabis sector took a sharp downturn. Here's a summary of what happened today.
Via Benzinga · November 6, 2024
Tilray, Trulieve And Other Cannabis Stocks Nosediving As Industry Faces New Wave Of Political Uncertaintybenzinga.com
Cannabis stocks plunge as Florida's legalization fails and GOP Senate control tempers expectations for industry growth.
Via Benzinga · November 6, 2024
Cannabis Reform Stumbles In 2024 Elections: A State-By-State Breakdown As Stocks Take A Hitbenzinga.com
Florida and the Dakotas reject cannabis measures, while Nebraska approves medical cannabis and Dallas decriminalizes. Explore each state's path forward.
Via Benzinga · November 6, 2024
Marijuana Capital Markets: Bright 2025 Outlook Amid Regulatory Shiftsbenzinga.com
Federal reform and banking access may drive cannabis capital markets in 2025. Discover why upcoming election changes could boost the industry.
Via Benzinga · November 4, 2024
Cannabis Stocks Sink Amid Broader Market Decline And Election Jittersbenzinga.com
Cannabis stocks drop amid broader market downturn and election uncertainty, with major players like Tilray and Aurora Cannabis w/ losses.
Via Benzinga · October 31, 2024
AdvisorShares MSOS Climbs 8% As Cannabis Rescheduling Sparks Investor Interestbenzinga.com
AdvisorShares MSOS ETF surges 8% as U.S. cannabis reform nears. Explore key investment signals and market opportunities.
Via Benzinga · October 23, 2024
'The Biggest Opportunities For Investors Outside AI': Optimism Reigns At Benzinga Conference Amid Talks Of Cannabis Rescheduling, Tech Advancesbenzinga.com
Cannabis leaders at the Benzinga Cannabis Capital Conference see rescheduling and banking reform as game-changers for the industry.
Via Benzinga · October 11, 2024
EXCLUSIVE: Weed Companies Will Be Treated Like Normal Businesses Once This Tax Provision Goes Away, Experts Saybenzinga.com
Marijuana companies would be "treated like normal businesses," If the oppressive restrictions of Section 280E of the Internal Revenue Code, which prevents cannabis businesses from deducting typical business expenses, go away.
Via Benzinga · October 8, 2024
Cannabis Investor Sentiment Softens As Institutional Confidence Wanes, Survey Showsbenzinga.com
Investor sentiment on cannabis turns neutral as delays in rescheduling and uplisting affect the market. Florida legalization also analyzed...
Via Benzinga · September 13, 2024